LZ Therapeutics

LZ Therapeutics is an early stage therapeutics company focused on neurology and its lead program LZT-1000 is for Parkinson’s disease.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Malvern, PA, USA
  • Currency USD
  • Founded December 2010

Company Summary

LZT-1000 offers a novel approach to treat Parkinson’s disease. Phase 2 clinical data in over 100 Parkinson’s patients have demonstrated a significant anti-Parkinsonian effect and excellent safety profile for the active moiety. In addition, clinical studies have indicated that LZT-1000 could potentially become the first Parkinson’s therapy able to slow progression of the underlying disease.

Team

  • Jyrki Mattila
    CEO

    - M.D., Ph.D.
    - 30 years in pharma and biotech – Auxilium and Orion Pharma (a world leader in PD market)
    - Developed Comtan and Stalevo for PD – sales $600M

  • Gerri Henwood
    Director

    - 35+ years in CRO, biotech and pharma - GSK
    - Serial entrepreneur - founder: IBAH, AUXL, Recro
    - Raised $300M, two successful IPOs and M&A exit

  • Floyd Bloom
    Director

    -M.D.
    - World leader in neuroscience – The Scripps Research Institute
    - Over 400 original publications on CNS disorders
    - Served as Editor-In-Chief of Science and Brain Research

  • Wayne Weisman
    Director

    - Managing Director, Partner, SCP-Vitalife
    - Long term investor in life science companies

  • Jyrki Mattila

Advisors

  • Saul-Ewing
    Lawyer
    Unconfirmed
    KMPG
    Accountant
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free